drugset / Trial / NCT01014429

Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01014429

Phase 1 Completed 21 enrolled Nerviano Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.

Timeline

Start
2009-11
Primary completion
2011-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Onvansertib Small molecule

Indications

No indication recorded.